199 related articles for article (PubMed ID: 29755111)
1. Genomic landscape and prognostic analysis of mantle cell lymphoma.
Yang P; Zhang W; Wang J; Liu Y; An R; Jing H
Cancer Gene Ther; 2018 Jun; 25(5-6):129-140. PubMed ID: 29755111
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
[TBL] [Abstract][Full Text] [Related]
3. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
Beà S; Valdés-Mas R; Navarro A; Salaverria I; Martín-Garcia D; Jares P; Giné E; Pinyol M; Royo C; Nadeu F; Conde L; Juan M; Clot G; Vizán P; Di Croce L; Puente DA; López-Guerra M; Moros A; Roue G; Aymerich M; Villamor N; Colomo L; Martínez A; Valera A; Martín-Subero JI; Amador V; Hernández L; Rozman M; Enjuanes A; Forcada P; Muntañola A; Hartmann EM; Calasanz MJ; Rosenwald A; Ott G; Hernández-Rivas JM; Klapper W; Siebert R; Wiestner A; Wilson WH; Colomer D; López-Guillermo A; López-Otín C; Puente XS; Campo E
Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18250-5. PubMed ID: 24145436
[TBL] [Abstract][Full Text] [Related]
4.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
5. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
6. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
Jing C; Zheng Y; Feng Y; Cao X; Xu C
Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
[TBL] [Abstract][Full Text] [Related]
8. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
[TBL] [Abstract][Full Text] [Related]
9. PAX5 aberrant expression incorporated in MIPI-SP risk scoring system exhibits additive value in mantle cell lymphoma.
Zhang X; Han Y; Nie Y; Jiang Y; Sui X; Ge X; Liu F; Zhang Y; Wang X
J Mol Med (Berl); 2023 May; 101(5):595-606. PubMed ID: 37126184
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.
Dong HJ; Zhou LT; Fang C; Fan L; Zhu DX; Wang YH; Li JY; Xu W
Med Oncol; 2012 Sep; 29(3):2166-73. PubMed ID: 22057359
[TBL] [Abstract][Full Text] [Related]
12. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Delfau-Larue MH; Klapper W; Berger F; Jardin F; Briere J; Salles G; Casasnovas O; Feugier P; Haioun C; Ribrag V; Thieblemont C; Unterhalt M; Dreyling M; Macintyre E; Pott C; Hermine O; Hoster E;
Blood; 2015 Jul; 126(5):604-11. PubMed ID: 26022239
[TBL] [Abstract][Full Text] [Related]
13. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
[TBL] [Abstract][Full Text] [Related]
15. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
Hoster E; Dreyling M; Klapper W; Gisselbrecht C; van Hoof A; Kluin-Nelemans HC; Pfreundschuh M; Reiser M; Metzner B; Einsele H; Peter N; Jung W; Wörmann B; Ludwig WD; Dührsen U; Eimermacher H; Wandt H; Hasford J; Hiddemann W; Unterhalt M; ;
Blood; 2008 Jan; 111(2):558-65. PubMed ID: 17962512
[TBL] [Abstract][Full Text] [Related]
16. Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.
Jeong S; Park YJ; Yun W; Lee ST; Choi JR; Suh C; Jo JC; Cha HJ; Jeong JY; Chang H; Cha YJ; Kim H; Park MJ; Song W; Cho EH; Jeong EG; Lee J; Park Y; Lee YS; Kim DJ; Lee HS
Sci Rep; 2020 Aug; 10(1):13359. PubMed ID: 32770099
[TBL] [Abstract][Full Text] [Related]
17. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
[TBL] [Abstract][Full Text] [Related]
18. TCL1 expression predicts overall survival in patients with mantle cell lymphoma.
Shin SJ; Roh J; Cha HJ; Choi YD; Kim JM; Min SK; Kim JE; Eom DW; Lee H; Kim HJ; Yoon DH; Suh C; Huh J
Eur J Haematol; 2015 Dec; 95(6):583-94. PubMed ID: 25688912
[TBL] [Abstract][Full Text] [Related]
19. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).
Geisler CH; Kolstad A; Laurell A; Räty R; Jerkeman M; Eriksson M; Nordström M; Kimby E; Boesen AM; Nilsson-Ehle H; Kuittinen O; Lauritzsen GF; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E;
Blood; 2010 Feb; 115(8):1530-3. PubMed ID: 20032504
[TBL] [Abstract][Full Text] [Related]
20.
Ferrero S; Rossi D; Rinaldi A; Bruscaggin A; Spina V; Eskelund CW; Evangelista A; Moia R; Kwee I; Dahl C; Di Rocco A; Stefoni V; Diop F; Favini C; Ghione P; Mahmoud AM; Schipani M; Kolstad A; Barbero D; Novero D; Paulli M; Zamò A; Jerkeman M; da Silva MG; Santoro A; Molinari A; Ferreri A; Grønbæk K; Piccin A; Cortelazzo S; Bertoni F; Ladetto M; Gaidano G
Haematologica; 2020 Jun; 105(6):1604-1612. PubMed ID: 31537689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
